Minimally Invasive Treatments for Liver Cancer

While surgical resection and chemotherapy have remained mainstays in the treatment of both primary and metastatic liver cancers, various minimally invasive techniques have been developed to treat patients for whom traditional approaches either are not available or have failed. Percutaneous ablation techniques such as radiofrequency, microwave, cryoablation, and irreversible electroporation are considered as potentially curative treatments in patients with hepatocellular carcinoma with early-stage tumors. Transarterial chemoembolization (TACE) and radioembolization with yttrium-90 (Y-90) are palliative treatments that have improved survival in patients with unresectable disease. In this chapter, we discuss these minimally invasive techniques, the criteria for selecting appropriate candidates for treatment, and potential limitations to their use

Minimally Invasive Therapies for Hepatocellular Carcinoma: Mechanisms of Local Control and Systemic Immunologic Response

Minimally invasive treatments for hepatocellular carcinoma (HCC) are a cornerstone in the management of this challenging disease. For many years, percutaneously guided ablative techniques, such as radiofrequency ablation (RFA), cryoablation, and microwave ablation (MWA), have successfully treated many different solid malignancies including HCC. Since the initial implementation of these ablative techniques, there have been many advances in the design, technique, and patient selection as well as investigation into the body’s response to treatment. The mechanisms of thermal-based ablative techniques, advantages and disadvantages of each technique, subsequent immunologic response following ablation, and advances in care that utilize combination therapy to potentiate the immunologic response creating a robust and long-term immunity to HCC are outlined in this chapter

Bedside Percutaneous Cholecystostomy

Although percutaneous cholecystostomy historically is an alternative to cholecystectomy, it is typically performed as a bridge to gallbladder removal. As a low mortality procedure, it proves itself a valuable tool in morbid patients such as the elderly and the critically ill who present with acute cholecystitis and as an alternate route for biliary access. In high-risk patients, PC can be performed at the patient’s bedside in patients who are too unstable to be transported outside the ICU. PC is performed using ultrasound, CT, or fluoroscopic guidance; however, bedside PC can only be performed using ultrasound. Ultrasound is readily available and portable and allows for real-time imaging. A 2010 study performed by Donkol et al. demonstrated success rates for CT (93%), US (46%), and fluoroscopy (62%). Though US had the lowest success rate, it remains the only option for those critically ill who cannot tolerate transportation or an immediate cholecystectomy. Contraindications of PC include hemorrhage, pericholecystic abscess, gallbladder tumor, etc. Complications include bile leak, hemorrhage, sepsis, bowel perforation, etc. The gallbladder is a small organ with much pathology. Having the knowledge and skill to adequately perform this procedure is essential, especially in patients with septic shock in need of source control

Mechanical Venous Thrombectomy for Deep Venous Thrombosis in Cancer Patients: A Single-Center Retrospective Study

PURPOSE: Venous thromboembolism (VTE) is a major contributor to the mortality of cancer patients. Mechanical thrombectomy (MT) is an endovascular technique that physically removes a thrombus without thrombolytics. The purpose of this study was to evaluate safety, efficacy, and clinical outcomes following MT for lower extremity DVT in cancer patients. METHODS: This single-center, retrospective study evaluated outcomes following MT of lower extremity DVT in cancer patients from November 2019 to May 2023. The primary outcome measure was clinical success, defined as a decrease in Villalta score by at least 2 points following the intervention. Secondary outcomes included repeat intervention-free survival and overall survival. Technical success was defined as restoring venous flow with mild (\u3c 10%) or no residual filling defect. RESULTS: In total, 90 patients and 113 procedures were included. Technical and clinical success was achieved in 81% and 87% of procedures performed. Repeat intervention-free survival at 1 month, 3 months, and 6 months post-procedure was 92%, 82%, and 77%, respectively. The complication rate was 2.7%. Pathologic analysis of the extracted thrombus revealed tumor thrombus in 18.4% (18/98) samples. Overall survival for the study cohort was 87% at 1 month, 74% at 3 months, and 62% at 6 months. Patients who were found to have tumor thrombi were noted to have a decreased overall survival compared to patients with non-tumor thrombi (P = 0.012). CONCLUSION: MT is safe and efficacious in reducing cancer patients\u27 VTE-related symptoms. The high rate of tumor thrombus in thrombectomy specimens suggests this phenomenon is more common than suspected

Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case report

Hemangiopericytoma/Solitary Fibrous Tumor (HPC/SFT) is a rare fibroblastic sarcoma characterized by hyper-vasculature and STAT6 trans-nuclear localization. Cystic HPC/SFT is extremely rare. Due to the scarcity of cystic HPC/SFT cases, diagnostic and treatment guidelines are not well established. To our knowledge, we present the first case of cystic HPC/SFT observed in the liver. In addition, the patient had over 6 years of recurrent hypervascular solid HPC/SFT in the brain, bone, leptomeninges, liver and lung prior to developing a cystic HPC/SFT. Briefly, a 37-year-old Caucasian female with a history of HPC/SFT presented with several enlarging cystic hepatic lesions on surveillance MRI. The cystic/nonenhancing nature of these liver metastases were confirmed by contrast-enhanced ultrasound. Due to diagnostic uncertainty, two of these hepatic cysts were removed laparoscopically and pathology confirmed cystic HPC/SFT with a high MIB-1 index. Previously, in 2014, the patient was diagnosed with solid intracranial grade III pseudopapillary mesenchymal HPC/SFT in the posterior fossa and underwent subtotal resection followed by external beam radiation. In 2017, she had recurrent intracranial, vertebral, and intraspinal intradural extramedullary HPC/SFTs followed by surgery, proton therapy, and SRS radiotherapy. In 2019, after an uneventful pregnancy and birth, routine surveillance revealed metastases in the liver requiring an extended right hepatectomy. In 2020-2021 two solid hypervascular hepatic HPC/SFT were found and treated with microwave ablation. Shortly afterwards, several rapidly growing hepatic cystic HPC/SFT lesions developed. Of note, she has not taken any systemic therapy, indicating the cystic tumors are from metastases rather than cystic degradation as a sequela of therapy. Overall, this case highlights that cystic metastasis are a potential clinical manifestation of solid HPC/SFT. Moreover, cystic HPC/SFT can co-exist with the more typical primary solid hypervascular HPC/SFTs in the same patient. Lastly, in this case cystic HPC/SFT had a higher growth rate and propensity to metastasize as compared to the solid equivalent.Peer reviewe

A case report: Retrograde arterial embolization of locally-injected SpaceOAR hydrogel material into the right common iliac artery bifurcation

Biodegradable hydrogel-based matrices are becoming more widely utilized for a variety of medical applications, including SpaceOAR which is a hydrogel injected into the recto-prostatic space under ultrasound guidance to protect the rectum during prostate radiation therapy. Although a greater number of these procedures are being performed, there are no case reports on the potential complications which may result. In this report, we present the first case of retrograde embolization of SpaceOAR hydrogel into the right common iliac artery during routine office administration, as well as subsequent interventional angiography, inpatient and outpatient management, and clinical and imaging results at 1.5-month patient follow-up

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma

Predicting outcomes in patients with hepatocellular carcinoma (HCC) who undergo locoregional therapies remains a substantial clinical challenge. The purpose of this study was to investigate pre-procedure diffusion weighted magnetic resonance imaging (DW-MRI) as an imaging biomarker for tumoral response to therapy for patients with HCC undergoing drug eluting embolic (DEE) chemoembolization and radioembolization. A retrospective review of HCC patients who underwent DEE chemoembolization or radioembolization was performed. Of the 58 patients who comprised the study population, 32 underwent DEE chemoembolization and 26 underwent radioembolization. There was no significant difference in median apparent diffusion coefficient (ADC) values across the two treatment groups (1.01 × 10−3 mm2/s, P = 0.25). The immediate objective response (OR) rate was 71% (40/56). Tumors with high ADC values were found to have a higher probability of OR within 90 days (odds ratio 4.4, P = 0.03). Moreover, index lesion specific progression free survival (PFS) was greater for high ADC tumors, independent of conventional predictors of treatment response (hazard ratio 0.44, P = 0.01). Low ADC was associated with poorer PFS (P = 0.02). Pre-procedure ADC < 1.01 × 10−3 mm2/s is an independent predictor of poorer immediate OR and index lesion specific PFS in patients with HCC undergoing DEE chemoembolization or radioembolization

Temporary Reversal of Hepatoenteric Collaterals during ⁹⁰Y Radioembolization Planning and Administration

Purpose: This paper aims to evaluate the safety and efficacy of the temporary redirection of blood flow of hepatoenteric collaterals using a balloon catheter in the common hepatic artery (CHA) to prevent the nontarget deposition of 90Y microspheres. Materials and Methods: In this retrospective single-center study of patients who received 90Y radioembolization (RE) from September 2010 to September 2015, diagnostic (67 patients) or treatment (72 patients) angiograms with the attempted use of a balloon catheter in the CHA to temporarily direct blood flow away from the hepatoenteric arteries were analyzed. SPECT/CT nuclear scintigraphy was performed after both diagnosis and treatment. Results: Overall, only 12 hepatoenteric arteries in 11 patients required embolization due to persistent hepatoenteric flow despite the use of the balloon occlusion technique in a total of 86 patients. Physicians performed the 90Y RE using balloon occlusion with glass (n = 22) or resin (n = 50) microspheres. Over 80% administration of the prescribed 90Y dose was accomplished in 34 (67%) resin and 20 (95%) glass microsphere patients. Post-treatment 90Y RE scintigraphy confirmed the absence of extrahepatic activity in all patients. One grade 2 gastrointestinal ulcer was present after 90 days of follow-up. Conclusion: Temporary CHA occlusion with a balloon catheter is a reliable and reproducible alternative to the conventional coil embolization of hepatoenteric arteries during diagnostic Tc-99m macroaggregated albumin and therapeutic 90Y RE delivery